US5422239A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunoassay utilizing monoclonal high affinity IgM antibodies
Assignee: General Hospital Corp
•
Filing: 1987-05-15
•
Granted: 1995-06-06
•
Expires: 2007-05-15
Abstract
Abstract Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of vital antigens.
Inventors
- 👤 Jack R. Wands
- 👤 Vincent R. Zurawski, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 01:38
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K16/00; C07K16/08; C07K16/081; C07K16/082; C07K16/10; A; A61; A61K; A61K39/00; C12; C12N; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S436/00; Y10S436/804; Y10S436/811; Y10S436/82; Y10S530/00; Y10S530/82; Y10S530/826; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
130 words
In an immunometric assay to determine the presence or concentration of an antigenic substance containing HBsAg determinants in a sample of a fluid comprising forming a ternary complex of a first labelled antibody, said antigenic substance, and a second antibody, said second antibody being bound to a solid carrier insoluble in said fluid, wherein the presence of the antigenic substance in the sample is determined by measuring either the amount of labelled antibody bound to the solid carrier, or the amount of unreacted labelled antibody, the improvement comprising employing IgM monoclonal antibodies which bind to HBsAg determinants per se and having an affinity for the antigenic substance containing HBsAg determinants of at least 10 9 liters/mole for each of said labelled antibody and said antibody bound to a solid carrier.
Claim 2
Dependent Claim
130 words
In an immunometric assay to determine the presence or concentration of an antigenic substance containing HBsAg determinants in a sample of a fluid comprising forming a ternary complex of a first labelled antibody, said antigenic substance, and a second antibody, said second antibody being bound to a solid carrier insoluble in said fluid, wherein the presence of the antigenic substance in the sample is determined by measuring either the amount of labelled antibody bound to the solid carrier, or the amount of unreacted labelled antibody, the improvement comprising employing IgM monoclonal antibodies which bind to HBsAg determinants per se and having an affinity for the antigenic substance containing HBsAg determinants of at least 10 9 liters/mole for each of said labelled antibody and said antibody bound to a solid carrier.
Claim 3
Dependent Claim
50 words
A process according to claim 1 wherein the fluid sample is first contacted with the second monoclonal antibody to form a binary complex of the antigenic substance and said second monoclonal antibody insoluble in the fluid and then contacted with said first labelled monoclonal antibody to form the ternary complex.
Claim 4
Dependent Claim
62 words
A process according to claim 1 wherein the fluid sample is first contacted with the second monoclonal antibody to form a binary complex of the antigenic substance and said second monoclonal antibody insoluble in the fluid; the sample separated from the solid carrier and the solid carrier contacted with a solution of said first labelled monoclonal antibody to form said ternary complex.
Claim 5
Dependent Claim
26 words
A process according to claim 3 wherein said solid carrier after formation of the ternary complex is washed to separate the fluid sample from the carrier.
Claim 6
Dependent Claim
16 words
A process according to claim 4 wherein the solid carrier is washed with phosphate buffered saline.
Claim 7
Dependent Claim
17 words
A process according to claims 1, 2 or 3 wherein the antigenic substance is Hepatitis B virus.
Claim 8
Dependent Claim
33 words
A process according to claims 1, 2 or 3 wherein the labelled antibody is labelled with a member selected from the group consisting of a radioactive isotope, an enzyme and a fluorogenic material.
Claim 9
Dependent Claim
15 words
A process according to claim 7 wherein said label is the radioactive isotope 125 I.
References Cited (Backward Citations)
US4248965A
Cited
US4098876A
Cited
GB2029571A
Cited
US4244940A
Cited
US4271145A
Cited
US4491632A
Cited
EP0038642A1
Cited
FR2481318A1
Cited
GB2074727A
Cited
US4361647A
Cited
EP0042755A2
Cited
EP0044219A1
Cited
EP0045103A2
Cited
US4376110A
Cited
EP0048357A1
Cited
EP0059754A1
Cited
EP0071635A1
Cited
US4837167A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-05 | 1998-12-05 | 1999-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-05 | 2002-12-05 | 2003-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-05 | 2006-12-05 | 2007-06-06 | $7700.00 | Window Closed / Lapsed |